ArticleTranslational cancer research2025
Prognostic factors and overall survival for second primary malignancies in myelodysplastic syndromes: a Cox regression coupled with competing risk model based on Surveillance, Epidemiology, and End Results (SEER) database.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prediction of overall survival in patients with hepatocellular carcinoma and second primary malignancies: a prognostic model based on the SEER database.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With therapeutic advancements improving survival outcomes in myelodysplastic syndromes (MDS), an increasing proportion of patients are at risk of developing second primary malignancies (SPMs). Nevertheless, the clinical profile, prognostic determinants, and overall survival (OS) of SPMs in this population remain inadequately characterized. This study sought to delineate the clinical features of SPMs in MDS patients and construct a predictive nomogram for overall survival (OS) in MDS-SPM (MSP) patients. Methods: Data were obtained from the Surveillance, Epidemiology, and End Results (SEER) database for the period 2000-2021. Cox regression and competing risk analyses were performed to identify prognostic factors. A nomogram was then constructed and validated to predict the OS of patients with SPMs after MDS. Results: A total of 2,967 eligible patients were included. The three most prevalent SPM sites were the respiratory system (18.03%), the urinary system (9.67%) and the colonand rectum (9.34%). The most common histological types of SPMs were adenomas and adenocarcinomas (38.93%), squamous cell neoplasms (9.91%) and ductal and lobular neoplasms (7.75%). Univariate and multivariate Cox regression analyses revealed that International Classification of Diseases for Oncology, Third Edition (ICD-O-3) histology, chemotherapy, age, the time interval between MDS and SPMs, SPM type, and marital status were associated with OS. Based on these factors, a nomogram was developed to predict OS. The time-dependent area under the curve (AUC) performed well in assessing the 5-year (0.69 and 0.7) and 7-year (0.73 and 0.74) OS of SPMs in the training and validation cohorts, demonstrating the nomogram's satisfactory discriminative ability. Conclusions: A prognostic nomogram was developed and validated to help clinicians assess the prognosis of MSP patients. The establishment of prognostic models can facilitate more comprehensive and precise treatment planning.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.